Implementing and Optimizing Biosimilar Use at Mayo Clinic

Jensen, Chelsee; Tichy, Eric M.; Lempke, Mary; Ewald, Adam M.; Erickson, Sara J.; Holm, Michelle R.; Soefje, Scott A.

doi:10.1016/j.mayocp.2022.02.015

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through provider education and leveraging the EHR to guide prescribers on FDA-approved indications, National Comprehensive Cancer Network guideline supported uses and ensuring an additional selection option to cover off-label use when PA has been obtained, we reduced off-label prescribing without adversely impacting the insurance collection rate. This adds to the body of evidence that leveraging tools within the EHR can result in healthcare savings 7 8. Furthermore, this report illustrates how patient and healthcare system burden can be reduced by prompting thought and direction when a medication has indication specific dose requirements.…”

mentioning

confidence: 85%

“…This adds to the body of evidence that leveraging tools within the EHR can result in healthcare savings. 7 8 Furthermore, this report illustrates how patient and healthcare system burden can be reduced by prompting thought and direction when a medication has indication specific dose requirements. Limitations existed in the ability to educate all prescribers across the health system, which may have influenced study results.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clicks away from reduced healthcare expenditures: leveraging the electronic health record to reinforce education efforts

Jensen

Honsey

Thielen

et al. 2022

BMJ Health Care Inform

View full text Add to dashboard Cite

ObjectivesLupron 11.25 mg has both a narrow indication and a high cost compared to other Lupron presentations. Prior to our study initiation there was no clear distinction between presentations when ordering within the health-system’s Electronic Health Record (EHR). This resulted in inappropriate product selection, payment and billing errors that negatively impact our healthcare system. To reinforce prior education efforts, a new approach was considered leveraging the EHR with information to steer prescribers to the proper Lupron presentation based on indication. This study aimed to reduce off-label prescribing for Lupron 11.25 mg (NDC 00074-3663-03) by 25% by 02/28/2022 without negatively impacting the insurance collection rate.MethodsBaseline Lupron 11.25 mg adult kit administrations one year prior to intervention and off-label prescribing was found to account for 22.7% of administrations. In December 2021 intervention order questions were added to Lupron 11.25 mg in the EHR. One and two-month data was obtained after implementing order questions within the EHR. Lupron 11.25 mg administrations were classified into one of four categories to determine impact on off-label prescribing.ResultsIn the one- and two-month post-implementation periods off-label prescribing was 0% and 15.3% respectively, a reduction of 22.7% to and 7.4% respectively from the baseline assessment. There were no clinical denials found in either post-implementation reporting period.ConclusionThis report adds to the body of evidence that leveraging the EHR can lead to healthcare savings and illustrates how patient and healthcare system burden can be reduced by prompting thought and direction when a medication has indication specific dose requirements.

show abstract

mentioning

confidence: 85%

mentioning

confidence: 99%

Clicks away from reduced healthcare expenditures: leveraging the electronic health record to reinforce education efforts

Jensen

Honsey

Thielen

et al. 2022

BMJ Health Care Inform

View full text Add to dashboard Cite

show abstract

“…The reasons for this are multifactorial and include among others the strong influence of innovative industry on law-making, physician uncertainty about the safety and efficacy of biosimilars compared with their reference product, complex litigation processes, and large numbers of patents enforced by originator manufacturers. 9e12 In this issue, Jensen et al 13 write euphemistically: "unique operational hurdles associated with the adoption of biosimilars pose challenges that have slowed the process in the US market. "…”

Section: Biosimilars In the United Statesmentioning

confidence: 99%

“…In this issue of Mayo Clinic Proceedings, a multidisciplinary team from Mayo Clinic report on how they organized the implementation of biosimilars throughout their organization. Jensen et al 13 started their biosimilar implementation strategy by aligning health care professionals through multidisciplinary team formation and selecting formulary-preferred biosimilars.…”

Section: Are These Biosimilar Implementation Principles Universal? Th...mentioning

confidence: 99%